Evotec Results Presentation Deck

in € m evotec PAGE 14 47.3 EBITDA H1 2020 -8.6 Portfolio¹) Double-digit organic EBITDA growth year-on-year EBITDA bridge H1 2020 - H1 2021 - Evotec SE and subsidiaries 38.6 EBITDA Q2 2020 excl. portfolio¹) ¹) Sanofi payment Q1 2020 5.0 Organic growth -7.4 fx effect 36.2 EBITDA H1 2021 • Pure organic growth of adjusted EBITDA in H1 reached 13% • fx effect of € 7.4 m amounts to -19% • Decrease of 23% mainly due to delay of milestones as well as planned investments at all functional levels securing growth and capacity

View entire presentation